The objective of this contract is to design and synthesis a new plga based nanoparticle with nanoparticle with optimal protein-adjuvant formulation combining both targeting and controlled delivery for…

Ended Definitive Contract Awarded Last action

Contract number
75N93020C00013
Awardee
Awarding agency
Obligated
$299,040

Award facts

Contract value 100% obligated
$299,040.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 7 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
San Diego, CA 92111, USA
Research
SBIR Program Phase I Action
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00006 -$960
Other Administrative Action P00005 · Vaccines enabling HIV prevention targeting germinal center enhancement with engineered slow release nanoparticles $0
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $300,000

About this award

This $299,040 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to design and synthesize a new PLGA-based nanoparticle with an optimal protein-adjuvant formulation that combines targeting and controlled delivery for immunization against HIV. This contract was set aside for small businesses and is part of a larger SBIR solicitation from NIAID and the Centers for Disease Control and Prevention (CDC) seeking proposals for innovative R&D to support their mission needs.

Description

The objective of this contract is to design and synthesis a new plga based nanoparticle with nanoparticle with optimal protein-adjuvant formulation combining both targeting and controlled delivery for immunization against HIV.

Quick answers

Who was awarded contract 75N93020C00013?

75N93020C00013 was awarded to Nanocomposix, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 1, 2020.

How much is contract 75N93020C00013 worth?

The government has obligated $299,040 on 75N93020C00013.

Was contract 75N93020C00013 competed?

The extent of competition for 75N93020C00013 was full and open competition after exclusion of sources. The government received 7 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award